Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:IMRANYSE:PBHNASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.21-0.3%$29.75$22.90▼$36.45$5.15B0.511.75 million shs375,631 shsIMRAIMARA$46.51+1.5%$17.12$0.97▼$6.32$1.22B1.09138,364 shs10,105 shsPBHPrestige Consumer Healthcare$84.72-0.9%$83.60$63.02▼$90.04$4.19B0.44297,669 shs82,181 shsPTCTPTC Therapeutics$50.44+3.3%$46.35$28.72▼$58.38$4.00B0.521.02 million shs477,467 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+1.43%+6.61%-1.54%-11.61%+33.72%IMRAIMARA0.00%-2.89%-19.42%+625.35%+625.35%PBHPrestige Consumer Healthcare-0.31%-0.54%+1.52%+1.33%+32.97%PTCTPTC Therapeutics+0.02%+6.31%-2.24%-5.73%+34.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.5476 of 5 stars3.43.00.04.23.41.71.9IMRAIMARAN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare3.5976 of 5 stars1.32.01.73.52.92.51.9PTCTPTC Therapeutics3.9556 of 5 stars4.31.00.04.42.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.77Moderate Buy$38.8524.47% UpsideIMRAIMARA 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3310.17% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$63.7526.39% UpsideCurrent Analyst Ratings BreakdownLatest IMRA, ALKS, PBH, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.40$2.34 per share13.32$9.05 per share3.45IMRAIMARAN/AN/A$0.62 per share75.24$3.44 per shareN/APBHPrestige Consumer Healthcare$1.14B3.68$4.97 per share17.03$36.10 per share2.35PTCTPTC Therapeutics$1.77B2.26$2.43 per share20.80($10.85) per share-4.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.3822.782.2023.57%30.80%19.09%7/23/2025 (Estimated)IMRAIMARA$1.49M$0.05930.39∞N/AN/A2.12%2.00%N/APBHPrestige Consumer Healthcare$209.34M$4.2919.8417.802.6919.13%12.36%6.39%8/7/2025 (Estimated)PTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/7/2025 (Estimated)Latest IMRA, ALKS, PBH, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AIMRAIMARAN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.24%N/A44.29%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65IMRAIMARAN/A48.9848.98PBHPrestige Consumer Healthcare0.563.682.20PTCTPTC TherapeuticsN/A2.102.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%IMRAIMARA49.28%PBHPrestige Consumer Healthcare99.95%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%IMRAIMARA37.30%PBHPrestige Consumer Healthcare1.60%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableIMRAIMARA4126.23 million16.45 millionNot OptionablePBHPrestige Consumer Healthcare54049.42 million48.75 millionOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableIMRA, ALKS, PBH, and PTCT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 3 at 9:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 2 at 1:52 PM | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)June 2 at 4:34 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 2 at 4:24 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 1 at 10:00 AM | prnewswire.comMackenzie Financial Corp Increases Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)June 1 at 4:32 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Ameriprise Financial Inc.June 1 at 3:19 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $63.75 Average Target Price from BrokeragesMay 31 at 2:21 AM | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 29, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMay 29, 2025 | americanbankingnews.comWells Fargo & Company Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) StockMay 28, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 27, 2025 | accessnewswire.comToronto Dominion Bank Invests $148.36 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $7.83 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 27, 2025 | marketbeat.comQuantinno Capital Management LP Makes New $436,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 26, 2025 | prnewswire.comWoodline Partners LP Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 26, 2025 | marketbeat.comState of Wyoming Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Has $465,000 Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)May 26, 2025 | marketbeat.comProShare Advisors LLC Buys 6,164 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)May 25, 2025 | marketbeat.comMillennium Management LLC Purchases 89,959 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)May 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRA, ALKS, PBH, and PTCT Company DescriptionsAlkermes NASDAQ:ALKS$31.21 -0.08 (-0.26%) As of 12:45 PM EasternAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.IMARA NASDAQ:IMRAIMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Prestige Consumer Healthcare NYSE:PBH$84.72 -0.77 (-0.90%) As of 12:40 PM EasternPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.PTC Therapeutics NASDAQ:PTCT$50.44 +1.61 (+3.30%) As of 12:46 PM EasternPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
